OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
March 01, 2021
The companies intend to design and implement algorithms for the early stages of research for drug discovery and development of drug candidates to treat Alzheimer’s disease.
The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.
February 17, 2021
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.
Salipro Biotech has been granted a European Patent for its novel method of direct extraction of membrane proteins and for the generation of libraries with Salipro particles.
February 16, 2021
PwC has teamed up with CPI on the Medicines Manufacturing Innovation Center to strengthen the UK’s position in advanced medicines manufacturing.
Connecticut Innovations has launched a campaign to highlight the growing companies, top talent, cutting-edge research, and quality of life in Connecticut’s life sciences ecosystem.
February 10, 2021
Representatives of industry organizations discuss crucial business, regulatory, science-based issues facing the industry.
February 04, 2021
The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.
February 01, 2021
Viewpoint: Mike Hennessy, Sr., founder and chairman of MJH Life Sciences, commends the leadership of the pharmaceutical industry in combatting the COVID-19 pandemic.
January 29, 2021
Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.
January 28, 2021
Nexelis’ recent acquisition of GSK’s Marburg, Germany-based vaccines clinical bioanalytical laboratory expands its bioanalytical capabilities.
January 15, 2021
This new agreement covers 1.25 million additional doses of the antibody cocktail containing casirivimab and imdevimab for the treatment of COVID-19.
The collaboration will focus on up to three types of lung and gastrointestinal cancers.
The first four investments of the new program will support clinical-stage biotechnology companies while new investments will include companies focused on oncology, rare disease, and inflammation and immunology.
The acquisition significantly expands Precision Medicine Group’s cell and gene therapy expertise.
January 07, 2021
Intravacc and Cristal Therapeutics have entered into a strategic collaboration for the development of novel vaccine programs against human diseases.
January 06, 2021
Vendors are finding ways to address the increasingly complex analytical challenges in the biopharmaceutical industry to further biotherapeutic development.
Demand for specific advanced laboratory skills creates a positive employment market.
January 02, 2021
After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.
Essential bio/pharma employees show hard work and dedication can pay off, for patients.